Abstract
Background: The inflammatory cascade following ST-elevation myocardial infarction (STEMI) involves complex cytokine interactions whose clinical utility remains undefined. We characterized the temporal dynamics of serum cytokine networks and their prognostic value for major adverse cardiac events (MACE).
Methods: In this prospective observational study, 312 consecutive STEMI patients undergoing primary PCI were enrolled. Serial serum samples were obtained at admission (T0), 6 hours (T6), 24 hours (T24), and 72 hours (T72) post-PCI. A 15-plex cytokine panel was analyzed using high-sensitivity electrochemiluminescence. Patients were followed for 12 months for MACE (cardiac death, reinfarction, heart failure hospitalization).
Results: Distinct cytokine trajectories were identified. IL-6 peaked earliest at T6 (median 34.2 pg/mL, IQR 18.7-52.1), while IL-8 peaked at T24 (22.4 pg/mL, IQR 15.3-31.8). Patients developing MACE (n=48, 15.4%) exhibited significantly higher IL-1β at T0 (3.2 vs 1.8 pg/mL, p<0.001), persistent IL-6 elevation, and blunted IL-10 response. Network analysis revealed stronger pro-inflammatory connectivity in MACE patients.
Conclusion: Early-phase cytokine profiling, particularly IL-1β at presentation and IL-6 kinetics, provides incremental prognostic information beyond traditional risk markers. These findings support cytokine-guided risk stratification in acute MI.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.